Skip to content

the treatment of hybrid exosomes for cartilage defect

Hybrid exosomes targeting delivery of CRISPR/Cas9 gene editing MMP-13 for cartilage defects

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041827
Enrollment
Unknown
Registered
2021-01-06
Start date
2021-01-10
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

case series:Nil

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Diseases: osteoarthritis of various causes; 2. Aged between 15 and 55 years, regardless of gender; 3. Defect area: 2-12cm2; 4. The defect depth: Outerbridge III/IV level; 5. Cartilage defect has received other treatments, but the symptoms have not improved or recurred; 6. If osteoarthritis is caused by the change of the joint force line, the joint deformity must be corrected at the same time to restore the normal force line; 7. Patients can adhere to strict postoperative rehabilitation procedures; 8. I or my legal representative have voluntarily accepted this treatment and have signed the Informed Consent; 9. Ability to cooperate in observation of efficacy and adverse events; 10. Women of childbearing age have negative pregnancy tests and agree to use effective contraception during the study period.

Exclusion criteria

Exclusion criteria: 1. BMI >35 [bmi = weight divided by height squared =kg/m2]; 2. X or O legs; 3. Have a history of severe drug allergy or allergic constitution; 4. Women during pregnancy or lactation; men and women during pregnancy; 5. Traditional Chinese medicine containing anti-inflammatory drugs was used for treatment within 2 weeks before the test; 6. Participate in other clinical trials within 1 month before the trial; 7. Patients who received other joint operations within 2 months before the trial; 8. Besides KOA and other joint disease complications, such as: joint local infection, systemic or rheumatoid arthritis, rickets, calcinosis articular cartilage disease, hemochromatosis, inflammatory arthritis, femoral head necrosis, Paget's disease (Paget 's diseases), hemophilia joint disease, infectious arthritis, Charcot arthropathy (Charcot' s diseases) fluff nodular synovitis, synovium cartilage tumour disease; 9. HIV antibody positive, hepatitis virus antibody positive, syphilis and other infectious diseases; 10. Have uncontrollable cardiovascular, kidney, liver, endocrine and other systemic diseases, such as diabetes; 11. Having a known or suspected malignant tumor; 12. A recent history of alcohol and drug abuse, or use of illicit drug therapy; 13. Other pathological, physiological or environmental conditions make it inconvenient for patients to participate in this study; 14. Patients who cannot strictly adhere to postoperative rehabilitation training; 15. The subject may be unable to complete the study due to other reasons, or the researcher considers it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
Repair effect of cartilage defect (Cell and animal experiments);

Countries

China

Contacts

Public ContactXu Xiao

Shenzhen Second People's Hospital

xuxiaoxx@qq.com+86 18899765299

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026